Argos Therapeutics, Inc. (ARGS) Posts Q1 Loss of $1.05/Share

Argos Therapeutics, Inc. (NASDAQ: ARGS) reported Q1 EPS of ($1.05), $0.59 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $798.8 thousand versus the consensus estimate of $1.26 million.

For earnings history and earnings-related data on Argos Therapeutics, Inc. (ARGS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14